We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Buruli Ulcer Diagnosed by Fluorescent Thin Layer Chromatography

By LabMedica International staff writers
Posted on 29 Nov 2015
Print article
Image: A small Buruli ulcer caused by Mycobacterium ulcerans (Photo courtesy of Dr. A. Chauty, AFRF, Benin).
Image: A small Buruli ulcer caused by Mycobacterium ulcerans (Photo courtesy of Dr. A. Chauty, AFRF, Benin).
Mycobacterium ulcerans infection, known as Buruli ulcer, is a disease of the skin and subcutaneous tissues which is an important but neglected tropical disease with its major impact in rural parts of West and Central Africa where facilities for diagnosis and management are poorly developed.

Since prevention is not possible in the absence of either an effective vaccine or a clear understanding of the mode of transmission, a major control strategy for Buruli ulcer is early detection and treatment, hinging on effective laboratory confirmation of suspected cases. Standard routine laboratory techniques for the confirmation of Buruli ulcer disease are M. ulcerans isolation by culture, histopathology, smear microscopy for acid-fast bacilli (AFB) and polymerase chain reaction (PCR).

A team of international scientists led by those at Kwame Nkrumah University of Science and Technology (KNUST) (Kumasi, Ghana) recruited patients from Buruli ulcer treatment centers from January 2014 to June 2014 in Benin, DR Congo, Ghana and Côte d’Ivoire if they had a skin lesion suspected to be caused by M. ulcerans infection. Samples were collected by fine needle aspiration (FNA) or swab according to whether the lesion was non-ulcerated or ulcerated respectively and by biopsy if obtained at surgery. If PCR for the M. ulcerans repeat sequence IS2404 was positive they were included as Buruli ulcer disease patients and if the PCR was negative they were included in the control group.

The team evaluated fluorescent thin layer chromatography (f-TLC) for detection of mycolactone in the laboratory using samples from patients with Buruli ulcer and patients with similar lesions that gave a negative result on PCR. The f-TLC used was a modification of an existing methodology. The TLC plates were placed on an ultra violet lamp with a 365 nm filter. The fluorescent band at retention factor 0.23 from the patient sample was compared to that of the standards to confirm the presence of mycolactone. Two readers were made to confirm the mycolactone test result before test result reporting and were blinded to the PCR test result.

There were 71 IS2404 PCR positive samples and 28 PCR negative samples which were used as controls. The scientists found that mycolactone can be detected in 73% of M. ulcerans infected samples by fluorescent thin layer chromatography. The technique was easy to perform and the result could be read within one hour. The sensitivity was higher than that of microscopy (30–60%) or culture (35%–60%) and compared favorably with that of histology (82%). There was no difference in sensitivity when FNA and swabs were compared although the number of FNA samples was small.

The authors concluded that that mycolactone can be detected from M. ulcerans infected skin tissue by f-TLC technique. The technique is simple, easy to perform and read with minimal costs. In this study it was undertaken by a member of the group from each endemic country. It is a potentially implementable tool at the district level after evaluation in larger field studies. The study was published on November 19, 2015, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:

Kwame Nkrumah University of Science and Technology 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.